Amphastar Pharmaceuticals (AMPH) Finished Goods (2016 - 2025)
Amphastar Pharmaceuticals has reported Finished Goods over the past 11 years, most recently at $29.6 million for Q4 2025.
- Quarterly results put Finished Goods at $29.6 million for Q4 2025, down 24.87% from a year ago — trailing twelve months through Dec 2025 was $29.6 million (down 24.87% YoY), and the annual figure for FY2025 was $29.6 million, down 24.87%.
- Finished Goods for Q4 2025 was $29.6 million at Amphastar Pharmaceuticals, down from $37.7 million in the prior quarter.
- Over the last five years, Finished Goods for AMPH hit a ceiling of $41.6 million in Q2 2025 and a floor of $14.5 million in Q1 2022.
- Median Finished Goods over the past 5 years was $25.7 million (2023), compared with a mean of $26.1 million.
- Biggest five-year swings in Finished Goods: soared 91.35% in 2023 and later dropped 24.87% in 2025.
- Amphastar Pharmaceuticals' Finished Goods stood at $17.7 million in 2021, then increased by 6.97% to $18.9 million in 2022, then surged by 31.99% to $24.9 million in 2023, then soared by 58.14% to $39.4 million in 2024, then dropped by 24.87% to $29.6 million in 2025.
- The last three reported values for Finished Goods were $29.6 million (Q4 2025), $37.7 million (Q3 2025), and $41.6 million (Q2 2025) per Business Quant data.